Russian Heart Failure Journal 2012year Effect of Torasemid on left ventricle myocardium hypertrophy


To access this material please log in or register

Register Authorize
2012/№3

Effect of Torasemid on left ventricle myocardium hypertrophy

Averin E. E.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: left ventricle hypertrophy, left ventricle, torasemide

DOI: 10.18087 / rhfj.2012.3.1687

Relevance.Currently 44.7 % of patients after the cardiac interventions become not capable to labour. This consequence compels searching ways of optimization of rehabilitation measures, including drug therapy. Objective. Study of dynamics of the LV myocardium weight index dynamics (LVMWI) and type of heart remodeling on the background of diuretics takeup with antialdosterone action. Materials and methods. The study included 109 patients after prosthetic repair of cardiac valves. They included 60 (55 %) women and 49 (45 %) men. The average age made 50.8±6.1 years. Patients were divided in 4 groups: Group 1 – patients taking Torasemide (Diuver, ТEVA, Israel); Group 2‑patients taking Toracemode and Spironolactone; Group 3 – patients taking Spironolactone; Group 4 – patients taking only base therapy. Results. Addition of Torasemide to therapy leads to a more expressed reduction of LVMWI (28.9 %, p<0.05), i.e. reduction of intensity of LV myocardium hypertrophy as compared to patients taking only basic therapy (8.7 %) and as compared to patients taking Spironolactone (20.7 %). In 25 % of patients taking Toracamide a normalization of LV remodeling values is observed. IN the group of patients taking Spironolcatone patients with concentric LV hypertrophy increased two-fold and with concentric remodeling – by 11.8 %. Conclusion. It’s necessary to conduct multicenter prospective randomixed double blind study on comparative evaluation of Torasemide and Spironolactone effect as well as their combination on LVMWI and type of heart remodeling in patients with LVH.
  1. Аверин Е. Е. Социально-правовые аспекты реабилитации кардиологических пациентов. Врач. 2010;7:19–22.
  2. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19 (7):1550–1558.
  3. Balogun М, Dunn F. Systolic and diastolic function following regression of left ventricular hypertrophy in hypertension. J Hypertens. 1991;9 (Suppl 5);21–26.
  4. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322 (22):1561–1566.
  5. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J. 1998;19 (7):990–1003.
  6. Аверин Е. Е., Лопатин Ю. М., Деларю В. В. Реабилитация кардиохирургических больных в России: медицинские, социальные, психологичсекие и правовые аспекты. Журнал Сердечная Недостаточность. 2012;13 (1):40–45.
Averin E. E. Effect of Torasemid on left ventricle myocardium hypertrophy. Russian Heart Failure Journal. 2012;13(3):158-161

To access this material please log in or register

Register Authorize
Ru En